AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35464483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 11
Study 35465706 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (ART-NQ) single doses of 20 mg/kg for artemisinin and 8 mg/kg for naphthoquine.
Number of subjects: 29
Study 35465706 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation for patients weighing ≥70 kg.
Number of subjects: 29
Study 35465803 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers (ARB)
Number of subjects: 0
Study 35465803 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study 35465803 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study 35465803 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 0
Study 35466039 — intervention group
Group type: EXPERIMENTAL
Intervention: One antipseudomonal class (e.g., beta-lactam)
Number of subjects: 751
Study 35466039 — intervention group
Group type: EXPERIMENTAL
Intervention: Two antipseudomonal classes (e.g., beta-lactam/aminoglycoside)
Number of subjects: 751
Study 35466039 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more antipseudomonal classes (e.g., beta-lactam/aminoglycoside/fluoroquinolone)
Number of subjects: 751
Study 35466039 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple antipseudomonal classes
Number of subjects: 751
Study 35466524 — intervention group
Group type: EXPERIMENTAL
Intervention: ADI-PEG20 (pegargiminase) combined with pemetrexed (500 mg/m²) and cisplatin (dosage not specified)
Number of subjects: 0
Study 35466707 — intervention group
Group type: EXPERIMENTAL
Intervention: G7 continuous glucose monitoring (CGM) system placed on the arm
Number of subjects: 155
Study 35466707 — intervention group
Group type: EXPERIMENTAL
Intervention: G7 continuous glucose monitoring (CGM) system placed on the abdomen
Number of subjects: 155
Study 35466707 — intervention group
Group type: EXPERIMENTAL
Intervention: G7 continuous glucose monitoring (CGM) system for ages 2 to 6 years
Number of subjects: 155
Study 35467123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dik ≥ 2 model
Number of subjects: 461
Study 35467123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dik ≥ 3 model
Number of subjects: 461
Study 35467123 — intervention group
Group type: EXPERIMENTAL
Intervention: Antonio > 1.225 model
Number of subjects: 461
Study 35467123 — intervention group
Group type: COMPARATOR
Intervention: Antonio > 1.225 model vs. Dik ≥ 3 model
Number of subjects: 461
Study 35467243 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa (eftoza) 2.5-15 mg/kg intravenously on day 1 or day 1/day 8 every 21 days (dose-escalation phase)
Number of subjects: 105
Study 35467243 — intervention group
Group type: EXPERIMENTAL
Intervention: Eftozanermin alfa (eftoza) 1.25-7.5 mg/kg once-weekly (QW) (dose-optimization phase)
Number of subjects: 105
Study 35467434 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention
Number of subjects: 0
Study 35467452 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-extremity revascularization (LER)
Number of subjects: 5614
Study 35467562 — intervention group
Group type: EXPERIMENTAL
Intervention: pH monitoring after POEM
Number of subjects: 0
Study 35467749 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib at 25 mg/m2 orally twice daily
Number of subjects: 0
Study 35467749 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 0
Study 35467818 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical donor (HID) transplantation
Number of subjects: 335
Study 35467818 — intervention group
Group type: COMPARATOR
Intervention: HLA-matched sibling donor (MSD) transplantation
Number of subjects: 335
Study 35468269 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment
Number of subjects: 260
Study 35468269 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 260
Study 35468336 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of BNT162b2 vaccine
Number of subjects: 11123
Study 35468336 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2 vaccine
Number of subjects: 11123
Study 35468618 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-ddBCMA (100 × 10^6 or 300 × 10^6)
Number of subjects: 13
Study 35468618 — intervention group
Group type: EXPERIMENTAL
Intervention: CART-ddBCMA
Number of subjects: 13
Study 35468680 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cells targeting immune checkpoint proteins (CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT)
Number of subjects: 0
Study 35468680 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-T cell therapy targeting checkpoint pathways
Number of subjects: 0
Study 35468690 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched BMA-matrix (CE group)
Number of subjects: 0
Study 35468690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured autologous bone marrow MSCs matrix (CC group)
Number of subjects: 0
Study 35468690 — intervention group
Group type: COMPARATOR
Intervention: Discectomy only (DO group)
Number of subjects: 0
Study 35468690 — intervention group
Group type: COMPARATOR
Intervention: Non-injured control (NC group)
Number of subjects: 0
Study 35468801 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 0
Study 35468860 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 disruptions at the structural and community level
Number of subjects: 50
Study 35468860 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative themes from interviews
Number of subjects: 50
Study 35469060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecanemab + Standard of Care (SoC)
Number of subjects: 0
Study 35469060 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 0
Study 35469288 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab
Number of subjects: 60
Study 35469288 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab and suprachoroidal injection of triamcinolone acetonide (4mg/0.1mL)
Number of subjects: 60
Study 35469391 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual EEG assessment
Number of subjects: 50
Study 35469391 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual grading of MRI
Number of subjects: 50
Study 35469391 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC analysis
Number of subjects: 50
Study 35469391 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG and MRI combined
Number of subjects: 50
Study 35469391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic damage in cortical gray matter
Number of subjects: 50
Study 35469391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic damage in deep gray nuclei
Number of subjects: 50
Study 35469443 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fosphenytoin plus oral tapering of phenytoin
Number of subjects: 15
Study 35469846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 2
Study 35469846 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS2870 (NADPH oxidase inhibitor)
Number of subjects: 2
Study 35469846 — intervention group
Group type: COMPARATOR
Intervention: Control (no antioxidant treatment)
Number of subjects: 2
Study 35470214 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 12206
Study 35470214 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 12206
Study 35470225 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate 30 mg plus meloxicam 30 mg
Number of subjects: 9
Study 35470301 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 0
Study 35470301 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0
Study 35470301 — intervention group
Group type: EXPERIMENTAL
Intervention: Future research
Number of subjects: 0
Study 35470301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratification system
Number of subjects: 0
Study 35470686 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI hemodynamic assessment
Number of subjects: 57
Study 35470686 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermodilution time at 30 minutes post-PCI
Number of subjects: 57
Study 35470715 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure (HF)
Number of subjects: 3959
Study 35470855 — intervention group
Group type: EXPERIMENTAL
Intervention: High consumption of ultra-processed foods (721 ± 341 g/d, 28% of total food intake)
Number of subjects: 632
Study 35470855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages
Number of subjects: 632
Study 35470855 — intervention group
Group type: EXPERIMENTAL
Intervention: Desserts
Number of subjects: 632
Study 35470855 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meats
Number of subjects: 632
Study 35470975 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cycling at 70% maximal oxygen uptake for 30 minutes
Number of subjects: 8
Study 35471132 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline testing for cancer predisposition
Number of subjects: 0
Study 35471240 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Video Game (AVG) intervention combined with multicomponent exercise for 5 months
Number of subjects: 28
Study 35471240 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily activities without modification)
Number of subjects: 28
Study 35471625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg, 100 mg, 200 mg
Number of subjects: 5704
Study 35471625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5704
Study 35472208 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 152
Study 35472215 — intervention group
Group type: EXPERIMENTAL
Intervention: modified WHO (mWHO) risk score
Number of subjects: 65
Study 35472215 — intervention group
Group type: EXPERIMENTAL
Intervention: CARPREG II risk score
Number of subjects: 65
Study 35472215 — intervention group
Group type: EXPERIMENTAL
Intervention: HARRIS risk score
Number of subjects: 65
Study 35472215 — intervention group
Group type: EXPERIMENTAL
Intervention: ZAHARA risk score
Number of subjects: 65
Study 35472215 — intervention group
Group type: EXPERIMENTAL
Intervention: CARPREG risk score
Number of subjects: 65
Study 35472243 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyPEPI1018 and Montanide ISA51VG adjuvant subcutaneously, combined with fluoropyrimidine/biologic
Number of subjects: 11
Study 35472295 — intervention group
Group type: COMPARATOR
Intervention: New Covid-19 vaccines
Number of subjects: 0
Study 35472295 — intervention group
Group type: COMPARATOR
Intervention: Active controls (existing vaccines)
Number of subjects: 0
Study 35473396 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid-Stimulating Hormone and Thyroid Hormones
Number of subjects: 0
Study 35473676 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (prescribed)
Number of subjects: 2519
Study 35473676 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (unprescribed)
Number of subjects: 2519
Study 35473709 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (modified to use non-fluorinated glucocorticoids)
Number of subjects: 0
Study 35473709 — intervention group
Group type: EXPERIMENTAL
Intervention: Il-6 inhibitors and monoclonal antibodies
Number of subjects: 0
Study 35473709 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific antiviral therapies
Number of subjects: 0
Study 35473709 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis against venous thromboembolism
Number of subjects: 0
Study 35473709 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory support (oxygen, non-invasive ventilation, prone position ventilation, intubation, ECMO)
Number of subjects: 0
Study 35473726 — intervention group
Group type: EXPERIMENTAL
Intervention: CL2020 cells (1.5 million cells for low-dose cohort, 15 million cells for high-dose cohort)
Number of subjects: 12
Study 35473725 — intervention group
Group type: EXPERIMENTAL
Intervention: National Early Warning Score (NEWS)
Number of subjects: 18889
Study 35473725 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS's respiratory rate component
Number of subjects: 18889
Study 35473725 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS's individual score components
Number of subjects: 18889
Study 35474180 — intervention group
Group type: EXPERIMENTAL
Intervention: mRS >1 at 30 days and mRS 0-1 at 90 days OR mRS >2 at 30 days and mRS 0-2 at 90 days
Number of subjects: 1339
Study 35474180 — intervention group
Group type: EXPERIMENTAL
Intervention: mRS 1 at 30 days to 2 at 90 days
Number of subjects: 1339
Study 35474180 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement in mRS between 30 and 90 days
Number of subjects: 1339
Study 35474746 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecdotal evidence and social media guidelines (Era 1)
Number of subjects: 0
Study 35474746 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprints and accelerated interventions (Era 2)
Number of subjects: 0
Study 35474746 — intervention group
Group type: EXPERIMENTAL
Intervention: Living, online clinical guidelines (Current Era)
Number of subjects: 0
Study 35475155 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy
Number of subjects: 492
Study 35475157 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/day) + ADT
Number of subjects: 206
Study 35475157 — intervention group
Group type: COMPARATOR
Intervention: Flutamide (375 mg/day) + ADT
Number of subjects: 206
Study 35475300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB with ropivacaine + plain lubricant)
Number of subjects: 258
Study 35475300 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (DPNB with ropivacaine + tetracaine gel)
Number of subjects: 258
Study 35475300 — intervention group
Group type: COMPARATOR
Intervention: Tetracaine gel group (DPNB with saline)
Number of subjects: 258
Study 35475358 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Microvascular Dysfunction (CMD)
Number of subjects: 2322
Study 35475358 — intervention group
Group type: EXPERIMENTAL
Intervention: INOCA (Ischemia with Nonobstructive Coronary Arteries)
Number of subjects: 2322
Study 35475358 — intervention group
Group type: EXPERIMENTAL
Intervention: Major adverse cardiovascular events (MACE)
Number of subjects: 2322
Study 35475570 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 35475789 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial alternating current stimulation with cognitive treatment
Number of subjects: 75
Study 35475789 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial alternating current stimulation
Number of subjects: 75
Study 35475885 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg DLI plus low-dose interleukin-2 (LD IL-2)
Number of subjects: 25
Study 35475910 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15 (0.5, 1, and 2 μg/kg subcutaneously 5 days per week for 2 weeks)
Number of subjects: 11
Study 35475910 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-15
Number of subjects: 11
Study 35475982 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training (40-minute immersive individual simulation training focusing on high-risk medications in older adults)
Number of subjects: 36
Study 35475982 — intervention group
Group type: COMPARATOR
Intervention: Control (online educational training)
Number of subjects: 36
Study 35476034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sleep (7-9 hours/night) and activity (>5000 steps/day)
Number of subjects: 120
Study 35476034 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate sleep (7-9 hours/night) but less activity (<5000 steps/day)
Number of subjects: 120
Study 35476127 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 recombinant protein vaccination (WT1-A10) with vaccine adjuvant AS01
Number of subjects: 0
Study 35476252 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiestrogen hormonal therapy
Number of subjects: 29
Study 35476252 — intervention group
Group type: COMPARATOR
Intervention: Control (non-cancer group)
Number of subjects: 29
Study 35476455 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion needle ablation (INA)
Number of subjects: 35
Study 35476550 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy for ER+/Basal tumors (15% of ER+, HER2- tumors reclassified by 80-GS)
Number of subjects: 1069
Study 35476550 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant therapy for ER+/Luminal subtype
Number of subjects: 1069
Study 35476823 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO
Number of subjects: 136
Study 35476823 — intervention group
Group type: EXPERIMENTAL
Intervention: ECHO Plus
Number of subjects: 136
Study 35476981 — intervention group
Group type: EXPERIMENTAL
Intervention: Germ-free mice introduced with a consortium of 26 human gut bacterial strains
Number of subjects: 0
Study 35476981 — intervention group
Group type: COMPARATOR
Intervention: Acute malnutrition
Number of subjects: 0
Study 35476994 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected cell clones
Number of subjects: 4
Study 35476994 — intervention group
Group type: EXPERIMENTAL
Intervention: Different assays for clonal expansion
Number of subjects: 4
Study 35477163 — intervention group
Group type: EXPERIMENTAL
Intervention: Quick Dementia Rating System (QDRS)
Number of subjects: 121
Study 35477175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) alone for 6 months
Number of subjects: 135
Study 35477175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of Hydroxyurea (HU) and thalidomide for 6 months
Number of subjects: 135
Study 35477368 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative binocular vision measures including stereopsis, ocular alignment, fusional vergence, vergence facility, convergence amplitude, and symptom survey.
Number of subjects: 73
Study 35477368 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased vergence facility and convergence amplitude compared to pre-presbyopes.
Number of subjects: 73
Study 35477380 — intervention group
Group type: EXPERIMENTAL
Intervention: HIP-REP intervention based on Activity of Daily Living
Number of subjects: 18
Study 35477380 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18
Study 35477432 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course neoadjuvant chemoradiotherapy (NCRT) plus tislelizumab followed by total mesorectal excision (TME)
Number of subjects: 50
Study 35477432 — intervention group
Group type: COMPARATOR
Intervention: Long course neoadjuvant chemoradiotherapy (NCRT)
Number of subjects: 50
Study 35477725 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD0004J08 (single dose via intramuscular injection)
Number of subjects: 0
Study 35478081 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (BGF)
Number of subjects: 0
Study 35478081 — intervention group
Group type: COMPARATOR
Intervention: Composite comparator (LAMA/LABA therapies)
Number of subjects: 0
Study 35478081 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF
Number of subjects: 0
Study 35478493 — intervention group
Group type: COMPARATOR
Intervention: Maternal obesity (OW)
Number of subjects: 0
Study 35478493 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher α-diversity and specific microbial taxa at 1 month
Number of subjects: 0
Study 35478493 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HMO concentrations
Number of subjects: 0
Study 35478493 — intervention group
Group type: COMPARATOR
Intervention: Elevated maternal BMI
Number of subjects: 0
Study 35478493 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall microbial richness
Number of subjects: 0
Study 35478711 — intervention group
Group type: EXPERIMENTAL
Intervention: CCCG-LBL-2016 regimen combined with dasatinib and prophylactic intrathecal infusion
Number of subjects: 1
Study 35478711 — intervention group
Group type: COMPARATOR
Intervention: CCCG-LBL-2016 regimen
Number of subjects: 1
Study 35478711 — intervention group
Group type: EXPERIMENTAL
Intervention: BCR-ABL tyrosine kinase inhibitor (TKI) dasatinib
Number of subjects: 1
Study 35478711 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI-based haploidentical allogeneic hematopoietic stem cell transplantation (haplo-allo-HSCT)
Number of subjects: 1
Study 35479184 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS/Sham SS
Number of subjects: 40
Study 35479184 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham rTMS/SS
Number of subjects: 40
Study 35479184 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS/SS
Number of subjects: 40
Study 35479184 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS/Sham SS
Number of subjects: 40
Study 35479300 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD+ participants looking at sad eyes
Number of subjects: 159
Study 35479300 — intervention group
Group type: COMPARATOR
Intervention: PTSD- participants looking at sad eyes
Number of subjects: 159
Study 35479300 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed participants looking at sad eyes
Number of subjects: 159
Study 35479300 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of avoidance symptoms with attention to sad eyes
Number of subjects: 159
Study 35479300 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to neutral and happy faces
Number of subjects: 159
Study 35480072 — intervention group
Group type: COMPARATOR
Intervention: 3DCRT (three-dimensional conformal radiotherapy)
Number of subjects: 300
Study 35480072 — intervention group
Group type: COMPARATOR
Intervention: IMRT (intensity modulated radiotherapy)
Number of subjects: 300
Study 35480072 — intervention group
Group type: EXPERIMENTAL
Intervention: MOSES > 0.20
Number of subjects: 300
Study 35480072 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MOSES > 0.70
Number of subjects: 300
Study 35480074 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intraoperative mechanical power
Number of subjects: 1191
Study 35480074 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-weighted average driving pressure
Number of subjects: 1191
Study 35480074 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of postoperative pulmonary complications
Number of subjects: 1191